Royal Bank of Canada
VYGR icon

Royal Bank of Canada’s Voyager Therapeutics VYGR Stock Holding History

Royal Bank of Canada’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Sell
647
-657
-50% -$2.59K ﹤0.01% 6633
2025
Q4 		$5K Sell
1,304
-241,368
-99% -$1.07M ﹤0.01% 6731
2025
Q3 		$1.13M Sell
242,672
-47,429
-16% -$172K ﹤0.01% 3890
2025
Q2 		$902K Buy
290,101
+265,388
+1,074% +$856K ﹤0.01% 3985
2025
Q1 		$84K Sell
24,713
-3,194
-11% -$14.9K ﹤0.01% 5326
2024
Q4 		$158K Buy
27,907
+2,059
+8% +$13.3K ﹤0.01% 5004
2024
Q3 		$151K Buy
25,848
+121
+0.5% +$880 ﹤0.01% 5041
2024
Q2 		$204K Buy
25,727
+3,445
+15% +$28.9K ﹤0.01% 4756
2024
Q1 		$208K Buy
22,282
+10,265
+85% +$86.7K ﹤0.01% 4657
2023
Q4 		$101K Buy
12,017
+5,540
+86% +$40.2K ﹤0.01% 5614
2023
Q3 		$50K Sell
6,477
-5,495
-46% -$50.2K ﹤0.01% 5787
2023
Q2 		$138K Sell
11,972
-35
-0.3% -$362 ﹤0.01% 5075
2023
Q1 		$93K Sell
12,007
-214
-2% -$1.7K ﹤0.01% 5238
2022
Q4 		$74K Buy
12,221
+217
+2% +$1.23K ﹤0.01% 5660
2022
Q3 		$71K Buy
12,004
+11,354
+1,747% +$72.7K ﹤0.01% 5542
2022
Q2 		$4K Hold
650
– – ﹤0.01% 6767
2022
Q1 		$5K Hold
650
– – ﹤0.01% 7268
2021
Q4 		$2K Hold
650
– – ﹤0.01% 7430
2021
Q3 		$2K Sell
650
-5,287
-89% -$17.2K ﹤0.01% 7369
2021
Q2 		$25K Buy
5,937
+3,660
+161% +$16.6K ﹤0.01% 6453
2021
Q1 		$11K Buy
2,277
+467
+26% +$3.18K ﹤0.01% 6776
2020
Q4 		$13K Sell
1,810
-2,600
-59% -$25K ﹤0.01% 6276
2020
Q3 		$47K Buy
4,410
+84
+2% +$986 ﹤0.01% 5367
2020
Q2 		$55K Sell
4,326
-134
-3% -$1.56K ﹤0.01% 5183
2020
Q1 		$41K Sell
4,460
-2,318
-34% -$26.6K ﹤0.01% 5259
2019
Q4 		$95K Buy
6,778
+1,783
+36% +$25.9K ﹤0.01% 5108
2019
Q3 		$86K Buy
4,995
+685
+16% +$14.4K ﹤0.01% 4876
2019
Q2 		$117K Buy
4,310
+62
+1% +$1.42K ﹤0.01% 4789
2019
Q1 		$82K Sell
4,248
-11,132
-72% -$145K ﹤0.01% 4892
2018
Q4 		$144K Sell
15,380
-10,590
-41% -$136K ﹤0.01% 4539
2018
Q3 		$492K Buy
25,970
+23,956
+1,189% +$460K ﹤0.01% 3910
2018
Q2 		$39K Buy
2,014
+404
+25% +$7.99K ﹤0.01% 5264
2018
Q1 		$30K Buy
+1,610
New +$34.8K ﹤0.01% 5301
2017
Q4 		– Sell
-2,368
Closed -$49K – 6927
2017
Q3 		$49K Buy
2,368
+2,243
+1,794% +$25.3K ﹤0.01% 5429
2017
Q2 		$1K Sell
125
-316
-72% -$3.18K ﹤0.01% 6440
2017
Q1 		$6K Sell
441
-415
-48% -$5.04K ﹤0.01% 6158
2016
Q4 		$11K Buy
856
+851
+17,020% +$10.9K ﹤0.01% 6055
2016
Q3 		$0 Buy
+5
New +$68 ﹤0.01% 6592

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royal Bank of Canada's VYGR Position: Q1 2026 in Review

Royal Bank of Canada reduced its Voyager Therapeutics (VYGR) stake by 50% in Q1 2026, selling an estimated $2.59K and leaving 647 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #6633.

Royal Bank of Canada first reported a position in VYGR in Q3 2016 and has held it in 38 quarters since. The position peaked at $1.13M in Q3 2025. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Royal Bank of Canada held 647 shares of Voyager Therapeutics worth $3K as of Q1 2026.
  • Royal Bank of Canada sold 657 Voyager Therapeutics shares in Q1 2026, an estimated $2.59K.
  • Voyager Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6633 holding.
  • Royal Bank of Canada first reported a position in Voyager Therapeutics in Q3 2016 and has held it in 38 quarters since.
  • Royal Bank of Canada's Voyager Therapeutics position peaked at $1.13M in Q3 2025.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.